XPAR
MEDCL
Market cap608mUSD
Jun 06, Last price
16.14EUR
1D
-1.04%
1Q
15.62%
IPO
122.62%
Name
Medincell SA
Chart & Performance
Profile
MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | 2016‑03 | |
Income | |||||||||
Revenues | 11,945 20.79% | 9,889 141.78% | |||||||
Cost of revenue | 35,653 | 32,616 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (23,708) | (22,727) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 88 | (3,766) | |||||||
Tax Rate | |||||||||
NOPAT | (23,796) | (18,961) | |||||||
Net income | (25,038) -21.78% | (32,010) 29.04% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 23,296 | 810 | |||||||
BB yield | -8.55% | -0.33% | |||||||
Debt | |||||||||
Debt current | 6,161 | 43,455 | |||||||
Long-term debt | 55,702 | 14,252 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 8,506 | 2,900 | |||||||
Net debt | 41,966 | 50,786 | |||||||
Cash flow | |||||||||
Cash from operating activities | (11,922) | (25,421) | |||||||
CAPEX | (324) | (1,027) | |||||||
Cash from investing activities | (613) | 1,254 | |||||||
Cash from financing activities | 25,528 | 6,016 | |||||||
FCF | (22,857) | (18,302) | |||||||
Balance | |||||||||
Cash | 19,460 | 6,467 | |||||||
Long term investments | 437 | 454 | |||||||
Excess cash | 19,300 | 6,427 | |||||||
Stockholders' equity | (71,838) | (49,963) | |||||||
Invested Capital | 98,481 | 65,146 | |||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 28,420 | 25,188 | |||||||
Price | 9.59 -2.24% | 9.81 32.21% | |||||||
Market cap | 272,543 10.30% | 247,099 33.93% | |||||||
EV | 314,509 | 329,642 | |||||||
EBITDA | (21,989) | (21,062) | |||||||
EV/EBITDA | |||||||||
Interest | 4,617 | 3,932 | |||||||
Interest/NOPBT |